Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial
Skin Research and Technology · 2024-04 · 30 (4)
DOI: 10.1111/srt.13689 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Skin Research and Technology, online erschienen am 02.04.2024. Verfasst von Farhad Mohammadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Hauptthemen laut MEDLINE: Melatonin, Psoriasis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research and Technology Department of Shahid Sadoughi University of Medical Sciences.
Abstract (Originalsprache)
Background
Considering the pathogenesis of psoriasis and also the anti‐oxidant, immunomodulatory, and anti‐inflammatory properties of rosuvastatin and melatonin, the current clinical trial aimed to evaluate the efficacy of topical rosuvastatin and melatonin in patients with mild to moderate psoriasis.
Methods
The current randomized placebo‐controlled clinical trial was conducted using a 3‐arm parallel group included 77 adult patients (≥18 years old) with mild to moderate plaque psoriasis. Patients were randomized into a 1:1:1 ratio to one of three groups to receive one of the three interventions: melatonin cream, 5.0% (w/w), rosuvastatin cream, 5.0% (w/w), or placebo cream with a similar transparent appearance twice a day for 12 weeks. The primary outcome was severity of the disease using Psoriasis Area Severity Index (PASI). The secondary outcomes included the Dermatological Sum Score (DSS) to assess the erythema, scaling, and plaque elevation and the Dermatology Life Quality Index (DLQI). Photographs of the lesions were also taken at the baseline and at different periodic intervals thereafter.
Results
Among 77 randomized patients, 52 (mean (SD) age, 40.67 (10.85) years; 22 (42.30%) men) completed the study. A significant reduction of 45% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 70% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 46% (mean (SD) of 2.91(1.85) to 1.57 (1.11)) and 77% (mean (SD) of 2.91 (1.85) to 0.87 (0.67)) in DSS score on days 30 and 60 with rosuvastatin cream, 5% w/w ( P < 0.001) compared with baseline was observed, respectively. Also a significant decrease of 35% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 51% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 40% (mean (SD) of 5.00 (1.58) to 3.00 (1.76))and 61% (mean (SD) of 5.00 (1.58) to 1.92 (1.71)) in DSS score on days 30 and 60 with melatonin cream, 5% w/w ( P < 0.001) compared with baseline were observed, respectively. In each of the melatonin or rosuvastatin groups, DLQI improved significantly on days 30 ( P < 0.0001) and 60 ( P < 0.001) while the changes in the control group were not significant.
Conclusion
The results of this clinical trial demonstrated that topical melatonin and rosuvastatin diminished the severity of mild to moderate plaque psoriasis with a satisfactory safety profile. Future clinical trials should assess both the long‐term efficacy and safety of melatonin and rosuvastatin creams in larger study populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
- Pharmaceutical Sciences Research Center, School of Pharmacy, Student Research Committee, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
- Department of Internal Medicine, Clinical Research Center, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
- Department of Dermatology, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
- Department of Clinical Pharmacy, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
ORCID-Profile: Fatemeh Saghafi
Förderung
- Research and Technology Department of Shahid Sadoughi University of Medical Sciences
Zitieren
APA
Mohammadi, F., Harofteh, F. Z., Sahebnasagh, A., Ghaneei, N., Ardakani, M. E. Z., & Saghafi, F. (2024). Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial. Skin Research and Technology, 30(4). https://doi.org/10.1111/srt.13689
Vancouver
Mohammadi F, Harofteh FZ, Sahebnasagh A, Ghaneei N, Ardakani MEZ, Saghafi F. Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial. Skin Research and Technology. 2024;30(4). doi:10.1111/srt.13689
BibTeX
@article{Mohammadi2024,
author = {Mohammadi, Farhad and Harofteh, Fatemeh Zare and Sahebnasagh, Adeleh and Ghaneei, Narges and Ardakani, Mohammad Ebrahim Zadeh and Saghafi, Fatemeh},
title = {Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial},
journal = {Skin Research and Technology},
year = {2024},
volume = {30},
number = {4},
doi = {10.1111/srt.13689}
}
EUVIMED